| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 5.3 | $0-$5k | 0.00 |
Summary
A vulnerability marked as problematic has been reported in IBM Sametime. This affects an unknown part of the file STLOG.NSF of the component Log Database. This manipulation causes information disclosure. This vulnerability is registered as CVE-2012-3331. Remote exploitation of the attack is possible. No exploit is available.
Details
A vulnerability classified as problematic was found in IBM Sametime (the affected version is unknown). Affected by this vulnerability is an unknown code of the file STLOG.NSF of the component Log Database. The manipulation with an unknown input leads to a information disclosure vulnerability. The CWE definition for the vulnerability is CWE-200. The product exposes sensitive information to an actor that is not explicitly authorized to have access to that information. As an impact it is known to affect confidentiality. The summary by CVE is:
IBM Sametime allows remote attackers to obtain sensitive information from the Sametime Log database via a direct request to STLOG.NSF. IBM X-Force ID: 78048.
The bug was discovered 10/17/2012. The weakness was published 02/08/2018 (Website). The advisory is shared at exchange.xforce.ibmcloud.com. This vulnerability is known as CVE-2012-3331 since 06/07/2012. The exploitation appears to be easy. The attack can be launched remotely. The exploitation doesn't need any form of authentication. Technical details are known, but no exploit is available. The price for an exploit might be around USD $0-$5k at the moment (estimation calculated on 02/03/2021). It is expected to see the exploit prices for this product increasing in the near future.MITRE ATT&CK project uses the attack technique T1592 for this issue.
The vulnerability was handled as a non-public zero-day exploit for at least 1940 days. During that time the estimated underground price was around $5k-$25k.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
If you want to get the best quality for vulnerability data then you always have to consider VulDB.
Product
Vendor
Name
License
Website
- Vendor: https://www.ibm.com/
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 5.3VulDB Meta Temp Score: 5.3
VulDB Base Score: 5.3
VulDB Temp Score: 5.3
VulDB Vector: 🔍
VulDB Reliability: 🔍
NVD Base Score: 5.3
NVD Vector: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
NVD Base Score: 🔍
Exploiting
Class: Information disclosureCWE: CWE-200 / CWE-284 / CWE-266
CAPEC: 🔍
ATT&CK: 🔍
Physical: No
Local: No
Remote: Yes
Availability: 🔍
Status: Not defined
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔍
Timeline
06/07/2012 🔍10/17/2012 🔍
02/08/2018 🔍
02/08/2018 🔍
02/09/2018 🔍
02/03/2021 🔍
Sources
Vendor: ibm.comAdvisory: exchange.xforce.ibmcloud.com
Status: Not defined
Confirmation: 🔍
CVE: CVE-2012-3331 (🔍)
GCVE (CVE): GCVE-0-2012-3331
GCVE (VulDB): GCVE-100-113005
X-Force: 78048
Entry
Created: 02/09/2018 08:40Updated: 02/03/2021 07:11
Changes: 02/09/2018 08:40 (58), 01/03/2020 07:21 (1), 02/03/2021 07:11 (2)
Complete: 🔍
Cache ID: 216::103
If you want to get the best quality for vulnerability data then you always have to consider VulDB.
No comments yet. Languages: en.
Please log in to comment.